share_log

Needham Maintains Buy on Nurix Therapeutics, Maintains $31 Price Target

Benzinga ·  Apr 2 09:20

Needham analyst Gil Blum maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $31 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment